Participants needed for study on shingles vaccine

Share on facebook
Share on twitter
Share on linkedin
Share on email

A new study being conducted by QualityMetric, which specializes in patient-reported outcomes research, is seeking to understand why patients in Canada who get the Shingrix vaccine do or do not get both doses.

The study will include input from patients, age 50 and older, who received the vaccine between January 2018 and March 2020. Shingrix is a 2-dose vaccine; the second dose should be administered 2-6 months after the first dose.

At this time, participants are needed who are age 50+ and meeting 1 of the following criteria:

  1. Adults who received only 1-dose of Shingrix (i.e., they did not finish the series)
  2. Adults who received both doses of Shingrix, but the second one was administered less than 2 months OR more than 6 months after the first

Qualified participants will conduct a 60-minute interview, and be required to show proof of vaccination record(s). They will receive a 255$ CAD honorarium.

QualityMetric’s partners at QualWorld are helping to manage the screening and scheduling for interested individuals. Interested individuals can contact [email protected] for more information and/or to determine if they are eligible to participate in the study.

This study is sponsored by GlaxoSmithKline (GSK).


282 Wright Avenue,
Toronto, ON, M6R 1L5

Factor-Inwentash Faculty of Social Work
University of Toronto

Join CanAge for FREE

®2020 CanAge Inc. All Rights Reserved

You're Registered

Thank you for registering! Details will be emailed to you as soon as possible.

You're Registered

Check your email for more details. Thank you for signing up. We look forward to seeing you soon!

Thank You

By becoming a CanAge member, you’re adding your voice to our calls for change in protecting and improving the lives of older Canadians.

Know someone else who might like to join ?

share this with a friend

Share on facebook
Share on twitter
Share on linkedin
Share on email
Skip to content